A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?

被引：1
|
作者：
Krafft, Ulrich [1 ,2 ]
Hadaschik, Boris A. [1 ,2 ]
Lueckerath, Katharina [2 ,3 ]
Herrmann, Ken [2 ,3 ]
机构：
[1] Univ Duisburg Essen, Univ Hosp Essen, Dept Urol, Essen, Germany
[2] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[3] Univ Duisburg Essen, Univ Hosp Essen, Dept Nucl Med, Essen, Germany
来源：
EUROPEAN UROLOGY | 2024年 / 85卷 / 03期
关键词：
D O I：
10.1016/j.eururo.2023.09.022
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Neoadjuvant Therapy in High-Risk Prostate Cancer
    Ashrafi, Akbar N.
    Yip, Wesley
    Aron, Monish
    [J]. INDIAN JOURNAL OF UROLOGY, 2020, 36 (04) : 251 - 261
  • [2] Neoadjuvant therapy for high-risk localized prostate cancer
    Evan Y. Yu
    William K. Oh
    [J]. Current Oncology Reports, 2003, 5 (3) : 250 - 257
  • [3] Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer
    Devos, Gaetan
    Devlies, Wout
    De Meerleer, Gert
    Baldewijns, Marcella
    Gevaert, Thomas
    Moris, Lisa
    Milonas, Daimantas
    Van Poppel, Hendrik
    Berghen, Charlien
    Everaerts, Wouter
    Claessens, Frank
    Joniau, Steven
    [J]. NATURE REVIEWS UROLOGY, 2021, 18 (12) : 739 - 762
  • [4] Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer
    Gaëtan Devos
    Wout Devlies
    Gert De Meerleer
    Marcella Baldewijns
    Thomas Gevaert
    Lisa Moris
    Daimantas Milonas
    Hendrik Van Poppel
    Charlien Berghen
    Wouter Everaerts
    Frank Claessens
    Steven Joniau
    [J]. Nature Reviews Urology, 2021, 18 : 739 - 762
  • [5] Neoadjuvant and adjuvant chemohormonal therapy in patients with high-risk and very high-risk prostate cancer: our experience
    Ustinova, T., V
    Nyushko, K. M.
    Bolotina, L., V
    Kharchenko, N., V
    Paychadze, A. A.
    Taraki, I. A.
    Alekseev, B. Ya
    Krasheninnikov, A. A.
    Kaprin, A. D.
    [J]. ONKOUROLOGIYA, 2018, 14 (03): : 58 - 67
  • [6] Neoadjuvant and adjuvant treatment in high-risk prostate cancer
    Bandini, Marco
    Fossati, Nicola
    Gandaglia, Giorgio
    Preisser, Felix
    Dell'Oglio, Paolo
    Zaffuto, Emanuele
    Stabile, Armando
    Gallina, Andrea
    Suardi, Nazareno
    Shariat, Shahrokh F.
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    Briganti, Alberto
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 425 - 438
  • [7] Oncological results of neoadjuvant chemohormonal therapy in patients with high and very high-risk prostate cancer
    Berkut, M., V
    Artemjeva, A. S.
    Reva, S. A.
    Tolmachev, S. S.
    Petrov, S. B.
    Nosov, A. K.
    [J]. ONKOUROLOGIYA, 2020, 16 (01): : 54 - 63
  • [8] Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer
    Dorff, Tanya B.
    Glode, L. Michael
    [J]. CURRENT OPINION IN UROLOGY, 2013, 23 (04) : 366 - 371
  • [9] Tissue biomarkers in patients with high-risk prostate cancer treated with neoadjuvant chemohormonal therapy
    Narita, Shintaro
    Nara, Taketoshi
    Chiba, Syuji
    Kanda, Sohei
    Numakura, Kazuyuki
    Saito, Mitsuru
    Inoue, Takamitsu
    Huang, Mingguo
    Nanjo, Hiroshi
    Habuchi, Tomonori
    [J]. CANCER SCIENCE, 2018, 109 : 1023 - 1023
  • [10] Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer
    Garzotto, M
    Myrthue, A
    Higano, CS
    Beer, TM
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (03) : 254 - 259
12345